Clinical Trial Update: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Context Therapeutics reports an ongoing Phase 1 study of CTIM-76 in platinum-resistant ovarian cancer and other advanced solid tumors, with recruitment currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Platinum-resistant Ovarian Cancer
• Testicular Cancer

Drugs mentioned

• CTIM-76

Snippet

Sponsor: Context Therapeutics Inc. | Conditions: Platinum-resistant Ovarian Cancer, Testicular Cancer | Phase 1 | Status: RECRUITING